377.90p+4.80 (+1.29%)04 Jul 2025, 17:15
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Haleon PLC Fundamentals

Company NameHaleon PLCLast Updated2025-07-04
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue8.984 bnMarket Cap£33.95 bn
PE Ratio23.76Dividend per Share£0.06
Dividend Yield1.77Dividend Cover2.53
EPS£0.16EPS Growth (%)0.38
PEG2.98DPS Growth (%)0.4762
Debt Ratio0.2944Debt Equity Ratio0.5329
Asset Equity Ratio2.1151Cash Equity Ratio0.1353
Quick Ratio0.7053Current Ratio0.98
Price To Book Value2.0734ROCE0

Haleon PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total
Prelim2025-04-242025-06-05GBP0.0460
Interim2024-08-152024-09-19GBP0.0200
Prelim2024-03-142024-05-16GBP0.0420
Interim2023-08-242023-10-05GBP0.0180
Prelim2023-03-162023-04-27GBP0.0240

Haleon PLC Company Financials

Assets202420232022
Tangible Assets£1.92 bn£1.90 bn£1.90 bn
Intangible Assets£26.21 bn£26.86 bn£28.44 bn
Investments£82.00 m00
Total Fixed Assets£28.60 bn£29.24 bn£30.76 bn
Stocks£1.19 bn£1.41 bn£1.35 bn
Debtors£1.90 bn£1.68 bn£1.88 bn
Cash & Equivalents£2.19 bn£994.00 m£606.00 m
Other Assets£383.00 m£480.00 m0
Total Assets£34.31 bn£34.05 bn£34.81 bn
Liabilities202420232022
Creditors within 1 year£5.81 bn£4.64 bn£4.37 bn
Creditors after 1 year£12.28 bn£12.69 bn£13.99 bn
Other Liabilities000
Total Liabilities£18.09 bn£17.33 bn£18.36 bn
Net assets£16.22 bn£16.73 bn£16.46 bn
Equity202420232022
Called up share capital£91.00 m£92.00 m£92.00 m
Share Premium£1.00 m00
Profit / Loss£1.91 bn£1.63 bn£1.62 bn
Other Equity£16.17 bn£16.61 bn£16.33 bn
Preference & Minorities£58.00 m£123.00 m£126.00 m
Total Capital Employed£16.22 bn£16.73 bn£16.46 bn
Ratios202420232022
Debt Ratio£0.35£0.35£0.38
Debt-to-Equity£0.53£0.53£0.61
Assets / Equity2.11512.11512.1151
Cash / Equity0.13530.13530.1353
EPS£0.15£0.11£0.11
Cash Flow202420232022
Cash from operating activities£2.30 bn£2.10 bn£2.06 bn
Cashflow before financing£764.00 m£532.00 m£8.97 bn
Increase in Cash£1.29 bn£398.00 m£190.00 m
Income202420232022
Turnover£11.23 bn£11.30 bn£10.86 bn
Cost of sales£4.41 bn£4.55 bn£4.28 bn
Gross Profit£6.82 bn£6.75 bn£6.58 bn
Operating Profit£2.21 bn£2.00 bn£1.82 bn
Pre-Tax profit£1.91 bn£1.63 bn£1.62 bn

Haleon PLC Company Background

SectorHealthcare
ActivitiesHaleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of salesfrom global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Latest Interim Date31 Jul 2025
Latest Fiscal Year End Date27 Feb 2025

Haleon PLC Directors

AppointedNamePosition
2025-06-11Mr. Alan James StewartIndependent Director
2023-12-19Mr. Manvinder Singh BangaNon-Executive Director,Senior Independent Non-Executive Director
2025-06-11Mr. Brian James McNamaraChief Executive Officer and Director
2025-05-19Ms. Blathnaid BerginIndependent Director
2025-07-02Ms. Dawn AllenDirector and Chief Financial Officer
2024-09-27Mr. Tobias HestlerChief Financial Officer and Director
2025-06-17Ms. Marie Anne AymerichIndependent Director
2025-05-02Ms. Asmita DubeyIndependent Director

Haleon PLC Contact Details

Company Name
Address
Telephone
Website

Haleon PLC Advisors